Production of nanobodies in Andean camelids and their most common applications: A general review in the medical field

C. P. Ortega1, L. M. Rivera2, L. E. Trujillo1,2

1Departamento de Ciencias de la Vida y la Agricultura, Laboratorio Multidisciplinario, Universidad de las Fuerzas Armadas – ESPE, Sangolquí, Ecuador.
2Centro de Nanociencia y Nanotecnología – CENCINAT, Universidad de las Fuerzas Armadas ESPE, Sangolquí, Ecuador.

Corresponding author: letrujillo3@espe.edu.ec

Abstract: The heavy chain fraction present in Camelidae antibodies is so-called nanobodies. They have different characteristics when compared to immunoglobulin G, like more diminutive size, higher affinity, shorter half-life in serum, etc. These proteins are codified by B lymphocytes cDNAs and can be produced in different hosts like Escherichia Coli, Pichia Pastoris, plant cells and even insect cells. Andean camelids have been mainly used in the Andean region of South America as transport means and source of raw materials like fibers and meat, then being of great economic importance. However, in Ecuador, the potential of these animals as a source of biomedical products has not been investigated or explored yet. Due to the scarce information related to these molecules and their industrial production in the country, this review aims to remark on the most common medical application of nanobodies produced from Andean camelids; also, industrial applications are described.

Key words: Cancer, Coronavirus, VHH, production, treatment, diagnosis.

Introduction

Camelid produces antibodies composed of heavy chain constant domains and a single variable domain; this variable domain is known as nanobody (Nb). It possesses a single antigen-binding domain called VHH1,2. Antibodies with a single variable chain, known as vNARs, have also been reported in the fish subclass Elasmobranchii to which sharks and rays belong5,10. Phylogenetic studies have shown that antibodies from Camelidae and Elasmobranchii evolved independently5,12. In recent years, Nb has been used as therapeutic agents, in diagnostic tests and as research tools6,7. Camelidae and Elasmobranchii possess different kinds of antibodies5, but only the antibodies that lack the light chains are of interest in this review.

Camelidae is a family that includes the old-world camelids: Camelus dromedarius (dromedaries), and C. bactrianus (camels), and the new-world camelids11–13. There are four species of new-world camelids in South America14,15; Lama glama (llamas), L. guanicoe (guanacos), Vicugna vicugna (vicuñas) and V. pacos (alpacas). All of them represent a genetic resource of great importance, not only from a scientific point of view16,18, since they could represent an opportunity for economic, social and technological development in Ecuador.

Nbs were first discovered and described by the Ha- mers-Casterman team19 at the Free University of Brussels while analyzing C. dromedarius serum. The potential use of Nbs in the medical field is focused on the prevention, diagnosis and disease treatments10,21. Additionally, several preclinical and clinical studies regarding their use in phases 1 and 22–24. The development of a drug at the laboratory scale until its sanitary registration takes about 10 years24,25. In fact, in 2019, the Food and Drug Administration (FDA) approved for the first time the therapeutic use of a humanized Nb27. Due to the great potential of Nbs, Steeland et al.28 concluded that these molecules could be positioned as pharmaceuticals in a short period for daily use.

The main objective of this review is to describe the most common medical application of nanobodies produced from Andean camelids to demonstrate the potential of these molecules as a medical product. In addition, a little overview of its recombinant production in different biotechnological hosts and other industrial fields is described.

Immunoglobulin G VS Nanobodies

Structurally, immunoglobulins G possess 2 light and 4 heavy chains. Heavy chains contain 3 constant domains and 1 variable domain (VH), while the light chains contain 1 constant and 1 variable domain (VL)29,30. However, Camelidae antibodies lack the light chain2, and their 3 chains are composed of 2 constant domains and 1 variable domain (Nb)32,33. In addition, Camelidae-like shark antibodies (which lack a light chain and possess 7 chains) are called New Antigen Receptors (NAR) antibodies34. They comprise 5 constant domains and 1 variable domain (vNAR)35. Figure 1 shows the structural comparison between mammalian IgG and the IgG-like antibodies from Elasmobranchii and Camelidae. Figure 2 shows the alignment of Elasmobranchii vNAR, Camelidae Nb and a Mus musculus heavy chain antibody sequences.

The figure shows the amino acid variation between vNAR, VHH and mAb heavy chains. In parenthesis protein name according to DATA bank information.

Despite the biotechnological importance of immunoglo-
bulin G, Nbs have certain differences over IgG, which are summarized in Table 1. The main Nbs disadvantage is their low half-life in human blood serum because they are filtered by the kidney in 26 to 60 minutes. However, they have low toxicity and can be eliminated from the human body by filtration by the kidneys. Nbs have a low immunogenicity risk profile, which drives their use to develop potential clinical applications. Using Nbs conjugated with small molecules like drugs, toxins, enzymes and imaging agents allows an approach to target sites with low systemic toxicity. In addition, Nbs do not present the solubility and aggregation problems typical of conventional antibodies due to their hydrophilicity.

The size of a camelid antibody is around 95 kDa due to the absence of the light chain; Elasmobranchii antibodies possess a variable region called vNAR and a constant region composed of five constant domains (cNAR). Camelidae antibodies are conformed by one variable heavy chain domain (VHH) and 2 constant heavy chain domains (CH2 and CH3). Mammalian antibodies are composed of one variable heavy chain domain (VH), three constant heavy chain domains (CH1, CH2, CH3) and a constant light chain domain (VL).

Figure 1. Structural comparison between IgG-like Elasmobranchii, Camelidae and Mammalian antibodies. Elasmobranchii antibodies possess a variable region called vNAR and a constant region composed of five constant domains (cNAR). Camelidae antibodies are conformed by one variable heavy chain domain (VHH) and 2 constant heavy chain domains (CH2 and CH3). Mammalian antibodies are composed of one variable heavy chain domain (VH), three constant heavy chain domains (CH1, CH2, CH3) and a constant light chain domain (VL).

How are Nanobodies produced?

The development of Nb libraries can be achieved from a naive or synthetic source or by immunization. All of them are great ways to get the appropriate Nb that best meets the final research goal. For this reason, Nbs are expressed and produced at a large scale in the chosen host. Libraries obtained by immunization are the most widely used and consist in injecting the animal with the correct antigen. Naive libraries are developed from non-immunized camelids blood, and synthetic libraries are developed from a determined sequence framework or the target antigen, from which randomization of oligonucleotides in the hypervariable regions is performed. The yields in the production of Nbs from immune libraries and synthetic libraries can vary significantly.

Figure 1 shows a general diagram for Nb production by immunization. This process starts with the inoculation of a young-adult camelid with 50 to 200 μg of the chosen antigen. After the first immunization, the animal must be injected from 4 to 8 times during 2 months. Once the immunization process is completed, the camelid's blood must be extracted and B lymphocytes purified. Further, B lymphocyte mRNA is isolated, purified and recovered to finally get the total complementary cDNA using polymerase chain reaction (PCR) techniques.

Then, a Nb library is generated from the above-obtai-
ned cDNA, for which the VHH regions are amplified using specific primers\textsuperscript{73,75}. Muyldermans (2021) research suggests that the amplification of the VHH regions should be performed using mainly the nested PCR technique\textsuperscript{64}.

From the PCR products, a gene library is generated\textsuperscript{67}; then the fragments must be chosen by a display technique; the most common technique is the phage display\textsuperscript{64}. The phage display library consists of bacteriophages with the antigenic molecule (Nb) in their coat; then, all the library is exposed to the specific antigen\textsuperscript{76}. Finally, the selected fragments are screened and then chosen those that produce specific Nbs for the particular antigen\textsuperscript{64,73,75,77}.

The selected VHH sequences are cloned at the industrial level in appropriate hosts like bacteria such as \textit{Escherichia coli}\textsuperscript{64,78,79} or yeasts such as \textit{Pichia pastoris}\textsuperscript{75}. Mammalian cells\textsuperscript{73}, insects or plants\textsuperscript{71} are also excellent options as industrial production hosts\textsuperscript{65}. Table 2 exposes the kind of expression and yields of the different host cells. Finally, the proteins are extracted and purified, generally using the ammonium sulfate precipitation method in conjunction with other types of chromatography\textsuperscript{73} as shown in Figure 1.

**Applications of camelid nanobodies in Human Health**

The small Nb size, joined with their high stability, solubility and a great capacity to recognize crypto-antigens place them as excellent alternatives for the prevention\textsuperscript{86}, diagnosis\textsuperscript{87,88} and human diseases treatment\textsuperscript{46,89,90}.

Disease diagnosis using Nbs points to: 1- the generation of images from tissues and organs\textsuperscript{57,91}; and 2- the performance of immunoassays to detect pathogen antigens\textsuperscript{89,92,93}.

Meanwhile, nanobodies as a therapeutic agents seek to attack an antigen, mainly to block virus replication\textsuperscript{94,95} or bacteria growth\textsuperscript{96}.

Another novel application is their use in antiphonic serums as neutralizers and blockers of toxins present in different types of poisons\textsuperscript{97-99}.

Finally, a search was made for medical applications of nanobodies developed in Andean camelids. About 518 articles were found using the "Publish or perish" program where Andean camelids were used. The reported applications belonged mainly to the health branch and articles published in the last 5 years including 50 scientific publications that were not review articles.

Using descriptive statistics and frequency histograms, it
### Table 1. Comparison between conventional antibodies and nanobodies.

<table>
<thead>
<tr>
<th>Immunoglobulin G</th>
<th>Nanobodies</th>
</tr>
</thead>
<tbody>
<tr>
<td>It has two variable domains: VH and VL. The latter provides stability and antigen-binding specificity.</td>
<td>The only variable domain it possesses is the VHHs; they have high stability despite lacking VLs.</td>
</tr>
<tr>
<td>They have a large size (150 kDa).</td>
<td>They are one-tenth the size of traditional antibodies (15 kDa), increasing the permeability of the molecule.</td>
</tr>
<tr>
<td>Low tissue permeability.</td>
<td>It can be entered into different types of tissues.</td>
</tr>
<tr>
<td>They may have flat surfaces, making them difficult to attach to specific antigen sites.</td>
<td>Its configuration allows it to bind to crypto antigens like protein cleavages and enzyme active sites.</td>
</tr>
<tr>
<td>It has low resistance to proteolysis and thermal denaturation.</td>
<td>They have a high resistance to proteolysis and thermal denaturation.</td>
</tr>
</tbody>
</table>

Information is taken from 15-45. VH=Variable Heavy domain, VL=Variable Light domain.

**Table 1.** Comparison between conventional antibodies and nanobodies.

---

**Figure 3.** 3D structure of antibody domains. a) VHH (1MEL). b) mAb of *Mus musculus* (1MLC). c) cNAR (1T6V). Information and images are taken from 15-45.
was determined that the most common application of Nbs is the treatment and diagnosis of infectious diseases (Figure 3). However, the condition for which the largest number of Nbs have been developed was cancer (Figure 4).

The 2020 pandemic greatly spurred the development of Nbs and other pharmaceuticals for the treatment and/or diagnosis of COVID-19\textsuperscript{100,101}. However, Nbs development focused on diagnosis, as shown in table 3; cancer treatment has been developed since before 2020.

Cancer is a disease in which uncontrolled cell multiplication can spread to other parts of the body\textsuperscript{102}. Alternatives for cancer prevention have existed since the 1700s\textsuperscript{103} and their treatments include surgeries, chemotherapies, radiotherapies, immunotherapies and hormone therapies\textsuperscript{104}. Nbs have a good synergy with these treatments\textsuperscript{105}, so they could be used together, although the full range of Nbs applications in cancer has not yet been explored thoroughly\textsuperscript{106,107}.

On the other hand, COVID-19 caused by SARS-CoV-2 generates affections on the respiratory system\textsuperscript{108}. On March 11 of 2020, the World Health Organization (WHO) declared a world pandemic for this infection\textsuperscript{109}. There is still no defined treatment for this disease, although monoclonal antibodies\textsuperscript{100,110} and nanobodies seem to be the best option to fight the virus\textsuperscript{111-113}. The future evolution of the virus must be awaited as it could generate less infectious and virulent variants or more aggressive strains resistant to the current preventive treatments\textsuperscript{114}.

### Applications of camelid nanobodies in different branches of industry

The main focuses of Nbs in plants are to protect crops by providing immunity against pathogens\textsuperscript{12,85} and rapid
Figure 5. Most common applications of nanobodies.

Figure 6. Diseases for which nanobodies were developed.
Detection of toxins that may affect food safety\(^{113}\). Passive immunity is the use of external antibodies to protect a patient\(^{115-116}\); this concept can be extrapolated to plants, where antibodies would protect them against pathogens\(^{115,119,120}\). On the other hand, Nbs can identify toxins in absorbance, fluorescence or Enzyme-Linked Immunosorbent Assay (ELISA) tests, depending on the toxin to be tested\(^{121-123}\).

In the livestock sector, the main Nbs application is on early disease detection\(^{124,125}\) to avoid zoonoses\(^{3,126,127}\). They can also help to determine the protein cellular activity\(^{140,141}\). This biological application could be used to alter cellular functions\(^{142}\), blocking or reducing the activity of endogenous proteins\(^{143}\).

Future Perspectives and Conclusions

This mini-review presented applications of nanobodies that could promote the use of Andean camels in Ecuador as new sources of products of high social, economic and public health interest.

The SARS-CoV-2 virus generated a global health crisis. Therefore, several methods for the diagnosis of COVID-19 were rapidly developed\(^{144}\). Nonetheless, there is still no defined treatment\(^{150,110}\). Becker’s study in 2020\(^{145} \) mentions that a great deal of research is being carried out, mainly focused on blocking the replication and translation of the virus RNA; moreover, some treatments seek to block the binding of the virus and its ACE2 receptors\(^{146,147}\). So, Nbs could be used as therapeutic molecules against COVID-19.

Ecuador has the greatest number of reptile species per unit area; one of the groups of greatest interest are snakes. Among them, about 35 species are known to be venomous, have been little studied\(^{150}\). In the past, serums to treat poisonings were produced by the "Instituto Nacional de Investigación en Salud Pública" INSI, but production was suspended in 2014 so only antivenoms were imported\(^{151}\). In 2022, INSI produced a batch of 300 experimental antivenom sera\(^{152}\). The Nbs could be used to act as high-affinity antivenom.

The incidence of cancer in Ecuador is 61% in women while 41% in men\(^{153}\); the types of cancer most reported in male patients are prostate, lymphoma and stomach\(^{154}\), while for female patients, they are breast cancer, cervix and lymphoid leukemia\(^{155}\). Nanobodies could be an interesting alternative for treating these types of cancer in Ecuador. However, the fact that they are rapidly filtered by the kidney makes them less attractive as a therapeutic alternative\(^{58}\).

In conclusion, the most common application of Nbs after analyzing more than 50 articles was the treatment and diagnosis of infectious diseases in cancer, so the future development of nanobodies should be linked to the treatment and diagnosis of these diseases. It is suggested that Nbs could achieve a balance between tissue permeability and a longer half-life in serum be developed for treating diseases such as cancer. However, other exciting applications in other fields are also not ruled out for the use of nanobodies.

### Bibliographic references

62. Protein Data Bank. 1MLC [Internet]. MONOCLONAL ANTIBODY FAB D44.1 RAISED AGAINST CHICKEN EGG-WHITE LYSOZYME COMPLEXED WITH LYSOZYME. 1995. Disponible en: https://www.rcsb.org/structure/1mlc

63. Protein Data Bank. 1T6V [Internet]. Crystal structure analysis of the nurse shark new antigen receptor (NAR) variable domain. Protein Data Bank. 1T6V [Internet]. 2004. Disponible en: https://www.rcsb.org/structure/1T6V


70. Zupectnic JM, Desai AA, Tessier PM. Facile isolation of high-affinity nanobodies from synthetic libraries using CDR-swapping mutagenesis. STAB Protoc. marzo de 2022;3(3):101101.

71. de Marco A. Recombinant expression of nanobodies and nanobody-derived immunoreagents. Protein Expr Purif. agosto de 2020;172:105645.


81. Iwaki T, Hara K, Umemura K. Nanobody production can be simplified by direct secretion from Escherichia coli. Protein Expr Purif. junio de 2020;170:105607.


95. DeMarco S. Snakebite antivenoms step into the future. 10 de septiembre de 2022;14.


